10% Owner New Enterprise Associates Makes $15M Open Market Purchase Post-IPO
Summary
A 10% owner, New Enterprise Associates 17, L.P., purchased $15 million worth of SpyGlass Pharma common stock on the open market, complementing a series of insider buys following the company's IPO.
Key Events
-
Significant Open Market Purchase
New Enterprise Associates 17, L.P., a 10% owner, acquired 937,500 shares of common stock for $15,000,000.00 at a price of $16.00 per share on February 9, 2026.
-
Post-IPO Insider Accumulation
This purchase is part of a broader pattern of significant insider accumulation, with multiple 10% owners and a director collectively buying $84.8 million in stock this week following SpyGlass Pharma's IPO.
-
Preferred Stock Conversion
The filing also reported the automatic conversion of 5,097,538 shares of various series of preferred stock into common stock, a standard event prior to the company's initial public offering.
Analysis
New Enterprise Associates 17, L.P., a significant 10% owner, demonstrated strong confidence in SpyGlass Pharma, Inc. by making a substantial $15 million open market purchase of common stock. This transaction, occurring shortly after the company's IPO and alongside a cluster of other insider buys, signals robust institutional backing and positive sentiment from key investors. The purchase price of $16.00 per share is notably below the current market price, suggesting the insider saw significant value at the time of the transaction. The conversion of preferred stock to common stock is a routine event associated with the IPO, but the cash purchase represents new capital deployment and a direct investment decision.
At the time of this filing, SGP was trading at $26.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $835.4M. The 52-week trading range was $24.71 to $28.93. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.